Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Greil R"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-13 z 13
    Tytuł:
    The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy.
    Autorzy:
    Mayr B; Institute of Sports Medicine, Prevention and Rehabilitation and Research Institute of Molecular Sports Medicine and Rehabilitation, Paracelsus Medical University, Salzburg, Austria.
    Reich B; Institute of Sports Medicine, Prevention and Rehabilitation and Research Institute of Molecular Sports Medicine and Rehabilitation, Paracelsus Medical University, Salzburg, Austria.
    Greil R; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria.
    Niebauer J; Institute of Sports Medicine, Prevention and Rehabilitation and Research Institute of Molecular Sports Medicine and Rehabilitation, Paracelsus Medical University, Salzburg, Austria.
    Pokaż więcej
    Źródło:
    Cancer medicine [Cancer Med] 2022 Dec; Vol. 11 (24), pp. 4946-4953. Date of Electronic Publication: 2022 May 18.
    Typ publikacji:
    Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Aromatase Inhibitors*/therapeutic use
    Breast Neoplasms*/drug therapy
    Female ; Humans ; Postmenopause ; Exercise ; Exercise Therapy
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial.
    Autorzy:
    Bjelic-Radisic V; Breast Unit, University Hospital Wuppertal, Heusnerstraße 40, 42283, Wuppertal, Germany. .; Department of Gynecology and Obstetrics, Medical University Graz, Graz, Austria. .
    Fitzal F; Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
    Knauer M; Breast Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland.
    Steger G; Department of Internal Medicine, Medical University of Vienna, Vienna, Austria.
    Egle D; Department of Gynecology and Obstetrics, Medical University Innsbruck, Inssbruck, Austria.
    Greil R; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular cancer Reseasrch, Paracelsus Medical University Salzburg, Salzburg, Austria.
    Schrenk P; Department of Surgery, Medical University Linz, Linz, Austria.
    Balic M; Division of Oncology, Department of Internal Medicine and Comprehensive Cancer Center, Medical University Graz, Graz, Austria.
    Singer C; Department of Gynecology and Obstetrics, Medical University Vienna, Vienna, Austria.
    Exner R; Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
    Soelkner L; Statistics Department, Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria.
    Gnant M; Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
    Pokaż więcej
    Corporate Authors:
    ABCSG
    Źródło:
    BMC cancer [BMC Cancer] 2020 May 06; Vol. 20 (1), pp. 392. Date of Electronic Publication: 2020 May 06.
    Typ publikacji:
    Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
    MeSH Terms:
    Patient Reported Outcome Measures*
    Quality of Life*
    Breast Neoplasms/*surgery
    Mastectomy/*mortality
    Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Neoplasm Metastasis ; Prognosis ; Prospective Studies ; Survival Rate ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.
    Autorzy:
    Papakonstantinou A; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Breast Cancer, Endocrine Tumours and Sarcoma Section, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
    Hedayati E; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Breast Cancer, Endocrine Tumours and Sarcoma Section, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
    Hellström M; CKC, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
    Johansson H; CKC, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
    Gnant M; Department of Surgery, Medical University of Vienna, Vienna, Austria.; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
    Steger G; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.; Department of Medical Oncology, Medical University, Vienna, Austria.; Gaston H. Glock Research Center, Medical University, Vienna, Austria.
    Greil R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.; IIIrd Medical Department, Cancer Cluster Salzburg, Salzburg Cancer Research Institute, Paracelsus Medical University Salzburg, Salzburg, Austria.
    Untch M; Department of Obstetrics and Gynecology, Helios Klinikum Berlin-Buch, Berlin, Germany.
    Moebus V; Department of Gynecology and Obstetrics, Klinikum Frankfurt Höchst, Academic Hospital of the Goethe University, Frankfurt, Germany.
    Loibl S; German Breast Group, Neu-Isenburg, Germany.
    Foukakis T; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Breast Cancer, Endocrine Tumours and Sarcoma Section, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
    Bergh J; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Breast Cancer, Endocrine Tumours and Sarcoma Section, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
    Matikas A; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Breast Cancer, Endocrine Tumours and Sarcoma Section, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
    Pokaż więcej
    Źródło:
    Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2020 Jan; Vol. 59 (1), pp. 75-81. Date of Electronic Publication: 2019 Oct 04.
    Typ publikacji:
    Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*adverse effects
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Breast Neoplasms/*blood
    Breast Neoplasms/*drug therapy
    Neutropenia/*chemically induced
    Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Breast Neoplasms/pathology ; Breast Neoplasms/surgery ; Chemotherapy, Adjuvant ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Docetaxel/administration & dosage ; Docetaxel/adverse effects ; Epirubicin/administration & dosage ; Epirubicin/adverse effects ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Middle Aged ; Neutropenia/drug therapy ; Patient Safety ; Treatment Outcome ; Young Adult
    SCR Protocol:
    FEC protocol
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
    Autorzy:
    Rinnerthaler G; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. .; Cancer Cluster Salzburg, 5020 Salzburg, Austria. .
    Gampenrieder SP; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. .; Cancer Cluster Salzburg, 5020 Salzburg, Austria. .
    Greil R; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. r.greil@salk.at.; Cancer Cluster Salzburg, 5020 Salzburg, Austria. r.greil@salk.at.
    Pokaż więcej
    Źródło:
    International journal of molecular sciences [Int J Mol Sci] 2019 Mar 05; Vol. 20 (5). Date of Electronic Publication: 2019 Mar 05.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Antineoplastic Agents, Immunological/*therapeutic use
    Breast Neoplasms/*drug therapy
    Maytansine/*analogs & derivatives
    Protein Kinase Inhibitors/*therapeutic use
    Receptor, ErbB-2/*metabolism
    Trastuzumab/*therapeutic use
    Ado-Trastuzumab Emtansine ; Clinical Trials as Topic ; Female ; Humans ; Maytansine/therapeutic use
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial.
    Autorzy:
    Westphal T; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
    Rinnerthaler G; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
    Gampenrieder SP; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
    Niebauer J; University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University Salzburg, Salzburg, Austria.
    Thaler J; IVth department of Internal Medicine with Hematology and Medical Oncolocy, Klinikum Wels-Grieskirchen, Klinikum Wels-Grieskirchen, Wels, Austria.
    Pfob M; mediFIT Wels, Medical Fitness and Training Center, Wels, Austria.
    Fuchs D; Department of Internal Medicine 3, Hematology and Oncology, Kepler University Hospital Med Campus III, Linz, Austria.
    Riedmann M; Department of Medical Statistics, Informatics and Health Economics, Medical University Innsbruck, Innsbruck, Austria.
    Mayr B; University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University Salzburg, Salzburg, Austria.
    Reich B; University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University Salzburg, Salzburg, Austria.
    Melchardt T; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
    Mlineritsch B; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
    Pleyer L; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria.
    Greil R; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria.
    Pokaż więcej
    Źródło:
    Cancer medicine [Cancer Med] 2018 Dec; Vol. 7 (12), pp. 5962-5972. Date of Electronic Publication: 2018 Nov 10.
    Typ publikacji:
    Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Patient Compliance*
    Breast Neoplasms/*therapy
    Exercise Therapy/*methods
    Aged ; Aged, 80 and over ; Aromatase Inhibitors/therapeutic use ; Exercise ; Female ; Humans ; Middle Aged
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites.
    Autorzy:
    Rinnerthaler G; IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. .; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg 5020, Austria. .; Cancer Cluster Salzburg, Salzburg 5020, Austria. .
    Hackl H; Division of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck 6020, Austria. .
    Gampenrieder SP; IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. .
    Hamacher F; IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. .
    Hufnagl C; IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. .
    Hauser-Kronberger C; Department of Pathology, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. .
    Zehentmayr F; Department of Radiotherapy, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. .
    Fastner G; Department of Radiotherapy, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. .
    Sedlmayer F; Department of Radiotherapy, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. .
    Mlineritsch B; IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. .; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg 5020, Austria. .; Cancer Cluster Salzburg, Salzburg 5020, Austria. .
    Greil R; IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. r.greil@salk.at.; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg 5020, Austria. r.greil@salk.at.; Cancer Cluster Salzburg, Salzburg 5020, Austria. r.greil@salk.at.
    Pokaż więcej
    Źródło:
    International journal of molecular sciences [Int J Mol Sci] 2016 Jan 26; Vol. 17 (2). Date of Electronic Publication: 2016 Jan 26.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Gene Expression*
    Genes, Essential*
    Breast Neoplasms/*genetics
    MicroRNAs/*genetics
    Breast Neoplasms/pathology ; Female ; Gene Expression Profiling/methods ; Gene Expression Profiling/standards ; Humans ; Neoplasm Metastasis ; Oligonucleotide Array Sequence Analysis/methods ; Oligonucleotide Array Sequence Analysis/standards
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
    Autorzy:
    Fitzal F; 1] Hospital of the Sisters of Charity, Breast Health Center, Linz, Austria [2] Department of Surgery and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
    Filipits M; Department of Oncology, Medical University Vienna, Vienna, Austria.
    Rudas M; Department of Pathology, Medical University Vienna, Vienna, Austria.
    Greil R; Department of Oncology, Salzburger Landesklinik, Salzburg, Austria.
    Dietze O; Department of Pathology, Salzburger Landesklinik, Salzburg, Austria.
    Samonigg H; Department of Oncology, Medical University Graz, Graz, Austria.
    Lax S; Department of Pathology, Medical University Graz, Graz, Austria.
    Herz W; Department of Surgery, KH Leoben, Leoben, Austria.
    Dubsky P; Department of Surgery and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
    Bartsch R; Department of Oncology, Medical University Vienna, Vienna, Austria.
    Kronenwett R; Sividon Diagnostics, Cologne, Germany.
    Gnant M; Department of Surgery and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
    Pokaż więcej
    Źródło:
    British journal of cancer [Br J Cancer] 2015 Apr 14; Vol. 112 (8), pp. 1405-10. Date of Electronic Publication: 2015 Mar 24.
    Typ publikacji:
    Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Reagent Kits, Diagnostic*
    Breast Neoplasms/*genetics
    Neoplasm Recurrence, Local/*genetics
    RNA, Neoplasm/*analysis
    Receptor, ErbB-2/*genetics
    Receptors, Estrogen/*genetics
    Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/pathology ; Breast Neoplasms/therapy ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Postmenopause ; Prospective Studies ; Risk Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
    Autorzy:
    Brodowicz T; Clinical Division of Oncology and Department of Medicine I, Medical University of Vienna and CECOG, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
    Lang I; Ráth György u. 7-9, National Institute of Oncology, H-1122 Budapest, Hungary.
    Kahan Z; Department of Oncotherapy, University of Szeged, H-6720 Szeged, Korányi fasor 12, H-6720 Szeged, Hungary.
    Greil R; IIIrd Medical Department, Paracelsus Medical University Hospital Salzburg and AGMT, Salzburg, Austria.
    Beslija S; Institute of Oncology, Clinical Center, University of Sarajevo, Bolnicka 27, 71000 Sarajevo, Bosnia and Herzegovina.
    Stemmer SM; Davidoff Center, Rabin Medical Center, Kaplan Street, Petah Tiqwa 49100, Israel.
    Kaufman B; Breast Oncology Institute, Sheba Medical Center, 52621 Tel Hashomer, Ramat-Gan, Israel.
    Petruzelka L; Department of Oncology, First Faculty of Medicine and General Teaching Hospital, Charles University Prague, U Nemocnice 2, 128 08 Prague 2, Czech Republic.
    Eniu A; Department of Breast Tumors, Cancer Institute Ion Chiricuţă, Republicii 34-36, 400015 Cluj-Napoca, Romania.
    Anghel R; University of Medicine and Pharmacy Bucharest, Soseaua Fundeni, Nr 252, Sector 2, Bucharest 022328, Romania.
    Koynov K; Department of Medical Oncology, Hospital Serdika, 6 Damyan Gruev street, 1303 Sofia, Bulgaria.
    Vrbanec D; Department of Medical Oncology, University Hospital Zagreb-Rebro, Medical University of Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.
    Pienkowski T; Oncology Department, European Health Centre Otwock, ul. Borowa 14/18, 04-500 Otwock, Poland.
    Melichar B; Department of Oncology, Palacký University Medical School, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
    Spanik S; St Elisabeth Cancer Institute, Heydukova 10, 812 50 Bratislava, Slovak Republic.
    Ahlers S; Biometrics, IST GmbH, Soldnerstrasse 1, 68219 Mannheim, Germany.
    Messinger D; Biometrics, IST GmbH, Soldnerstrasse 1, 68219 Mannheim, Germany.
    Inbar MJ; Oncology Division, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 64239, Israel.
    Zielinski C; Clinical Division of Oncology and Department of Medicine I, Medical University of Vienna and CECOG, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
    Pokaż więcej
    Źródło:
    British journal of cancer [Br J Cancer] 2014 Nov 25; Vol. 111 (11), pp. 2051-7. Date of Electronic Publication: 2014 Sep 30.
    Typ publikacji:
    Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antibodies, Monoclonal, Humanized/*administration & dosage
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Breast Neoplasms/*drug therapy
    Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Bevacizumab ; Breast Neoplasms/chemistry ; Breast Neoplasms/mortality ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Receptor, ErbB-2/analysis ; Risk Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
    Autorzy:
    Dubsky P; Department of Surgery and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
    Brase JC
    Jakesz R
    Rudas M
    Singer CF
    Greil R
    Dietze O
    Luisser I
    Klug E
    Sedivy R
    Bachner M
    Mayr D
    Schmidt M
    Gehrmann MC
    Petry C
    Weber KE
    Fisch K
    Kronenwett R
    Gnant M
    Filipits M
    Pokaż więcej
    Corporate Authors:
    Austrian Breast and Colorectal Cancer Study Group (ABCSG)
    Źródło:
    British journal of cancer [Br J Cancer] 2013 Dec 10; Vol. 109 (12), pp. 2959-64. Date of Electronic Publication: 2013 Oct 24.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Breast Neoplasms/*metabolism
    Breast Neoplasms/*pathology
    Receptor, ErbB-2/*biosynthesis
    Receptors, Estrogen/*biosynthesis
    Anastrozole ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Cell Differentiation/physiology ; Cell Growth Processes/physiology ; Clinical Trials, Phase III as Topic ; Female ; Gene Expression Profiling ; Humans ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/pathology ; Nitriles/administration & dosage ; Prognosis ; Proportional Hazards Models ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/genetics ; Receptors, Estrogen/metabolism ; Retrospective Studies ; Signal Transduction ; Tamoxifen/administration & dosage ; Tamoxifen/therapeutic use ; Treatment Outcome ; Triazoles/administration & dosage
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
    Autorzy:
    Gnant M; Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. />Pfeiler G
    Stöger H
    Mlineritsch B
    Fitzal F
    Balic M
    Kwasny W
    Seifert M
    Stierer M
    Dubsky P
    Greil R
    Steger G
    Samonigg H
    Fesl C
    Jakesz R
    Pokaż więcej
    Źródło:
    British journal of cancer [Br J Cancer] 2013 Aug 06; Vol. 109 (3), pp. 589-96. Date of Electronic Publication: 2013 Jul 18.
    Typ publikacji:
    Journal Article; Multicenter Study; Randomized Controlled Trial
    MeSH Terms:
    Body Mass Index*
    Aromatase Inhibitors/*administration & dosage
    Breast Neoplasms/*drug therapy
    Neoplasms, Hormone-Dependent/*drug therapy
    Nitriles/*administration & dosage
    Triazoles/*administration & dosage
    Adolescent ; Adult ; Anastrozole ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/adverse effects ; Aromatase Inhibitors/adverse effects ; Chemotherapy, Adjuvant ; Drug Administration Schedule ; Female ; Humans ; Middle Aged ; Nitriles/adverse effects ; Obesity/physiopathology ; Overweight/physiopathology ; Postmenopause ; Retrospective Studies ; Triazoles/adverse effects ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14.
    Autorzy:
    Tausch C; Breast Center, Seefeldstrasse 214, Zürich, Switzerland. />Steger GG
    Haid A
    Jakesz R
    Fridrik MA
    Reitsamer R
    Pöstlberger S
    Lang A
    Gnant M
    Greil R
    Pokaż więcej
    Źródło:
    The breast journal [Breast J] 2011 May-Jun; Vol. 17 (3), pp. 230-8. Date of Electronic Publication: 2011 Mar 31.
    Typ publikacji:
    Journal Article; Multicenter Study; Randomized Controlled Trial
    MeSH Terms:
    Sentinel Lymph Node Biopsy*
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Breast Neoplasms/*drug therapy
    Breast Neoplasms/*pathology
    Adult ; Aged ; Breast Neoplasms/surgery ; Combined Modality Therapy ; Docetaxel ; Epirubicin/administration & dosage ; False Negative Reactions ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Middle Aged ; Prospective Studies ; Sensitivity and Specificity ; Taxoids/administration & dosage
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
    Autorzy:
    Michlmayr A; Department of Surgery, Medical University of Vienna, A-1090, Vienna, Austria.
    Bachleitner-Hofmann T
    Baumann S
    Marchetti-Deschmann M
    Rech-Weichselbraun I
    Burghuber C
    Pluschnig U
    Bartsch R
    Graf A
    Greil R
    Allmaier G
    Steger G
    Gnant M
    Bergmann M
    Oehler R
    Pokaż więcej
    Źródło:
    British journal of cancer [Br J Cancer] 2010 Oct 12; Vol. 103 (8), pp. 1201-8. Date of Electronic Publication: 2010 Sep 28.
    Typ publikacji:
    Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Breast Neoplasms/*diagnosis
    Breast Neoplasms/*drug therapy
    Carcinoma, Ductal, Breast/*diagnosis
    Carcinoma, Ductal, Breast/*drug therapy
    Complement System Proteins/*analysis
    Adult ; Aged ; Biomarkers, Pharmacological/analysis ; Biomarkers, Pharmacological/blood ; Biomarkers, Pharmacological/metabolism ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/blood ; Breast Neoplasms/metabolism ; Carcinoma, Ductal, Breast/blood ; Carcinoma, Ductal, Breast/metabolism ; Complement System Proteins/drug effects ; Complement System Proteins/metabolism ; Docetaxel ; Dose-Response Relationship, Drug ; Epirubicin/administration & dosage ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Plasma/chemistry ; Plasma/drug effects ; Predictive Value of Tests ; Taxoids/administration & dosage ; Validation Studies as Topic
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Autorzy:
    Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna Medical University, Vienna General Hospital, Waehringer Guertel 18-20, Vienna A-1090, Austria. />Jonat W
    Gnant M
    Mittlboeck M
    Greil R
    Tausch C
    Hilfrich J
    Kwasny W
    Menzel C
    Samonigg H
    Seifert M
    Gademann G
    Kaufmann M
    Wolfgang J
    Pokaż więcej
    Corporate Authors:
    ABCSG and the GABG
    Źródło:
    Lancet (London, England) [Lancet] 2005 Aug 6-12; Vol. 366 (9484), pp. 455-62.
    Typ publikacji:
    Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Agents, Hormonal/*therapeutic use
    Aromatase Inhibitors/*therapeutic use
    Breast Neoplasms/*drug therapy
    Nitriles/*therapeutic use
    Tamoxifen/*therapeutic use
    Triazoles/*therapeutic use
    Aged ; Anastrozole ; Antineoplastic Agents, Hormonal/adverse effects ; Aromatase Inhibitors/adverse effects ; Breast Neoplasms/metabolism ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Disease Progression ; Disease-Free Survival ; Female ; Humans ; Nitriles/adverse effects ; Postmenopause ; Prospective Studies ; Randomized Controlled Trials as Topic ; Receptors, Estrogen/analysis ; Tamoxifen/adverse effects ; Triazoles/adverse effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-13 z 13

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies